Health Catalyst Inc. (NASDAQ:HCAT) does about 586.15K shares in volume on a normal day but saw 381618 shares change hands in Friday trading. The company now has a market cap of 751.98M USD. Its current market price is $13.52, marking a decrease of -2.87% compared to the previous close of $13.92. The 52 week high reached by this stock is $29.23 whilst the lowest price level in 52 weeks is $6.40. The script in recent trading has seen the stock touch a high of $13.95 and a low of $13.27.
Health Catalyst Inc. (HCAT) has a 20-day trading average at $13.92 and the current price is -53.75% off the 52-week high compared with 111.25% distance from its 52-week low. The 50-day simple moving average of the closing price is $12.16 and its 200-day simple moving average is $12.29. If we look at the stock’s price movements over the week, volatility stands at 4.62%, which increases to 4.92% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 51.94 to suggest the stock is neutral.
15 analysts observing the Health Catalyst Inc. (HCAT) stock have set the 12-month price targets for the company’s shares at between $8.00 and $17.00. The consensus objective for the share price is $13.46, suggesting that the stock has a potential downside of -0.45% over the period. The median price target is 9.87% away from the current levels at $15.00.
FactSet Research has provided data showing that 15 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 8 analysts have rated it as a buy and 7 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on January 03, 2023 when Evercore ISI downgraded the stock to “In-line” and issued a price target of between $10 and $11. RBC Capital Mkts downgraded its price target at $19-$9.
The current price level is -2.66%, 11.83%, and 9.93% away from its SMA20, SMA50, and SMA200 respectively, with the HCAT price moving above the 50-day SMA on February 17. Health Catalyst Inc. (HCAT) stock is down -2.59% over the week and 6.21% over the past month. Its price is 27.19% year-to-date and -54.12% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$0.13 above consensus estimates by $0.06. The company’s next earnings report is expected on 05/04/2023, with forecasts estimating quarterly EPS at -$0.11 and -$0.34 for whole year. HCAT’s earnings per share are forecast to grow by 24.40% this year and 26.50% over next year. Expected sales for next quarter are $71.65 million, which analysts say will come at $275.38 million for the current fiscal year and next year at $299 million. In addition, estimates put the company’s current quarterly revenue at an average of $68.26 million.
To reach the target analysts have set, the stock logically needs to shrink -0.45 percent from here.
Outstanding shares total 54.30M with insiders holding 2.45% of the shares and institutional holders owning 92.27% of the company’s common stock. The company has a return on investment of -19.50% and return on equity of -31.50%. The beta has a value of 1.28. Price to book ratio is 1.67 and price to sales ratio is 2.77.
Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard Small Cap Index Fund, which added 7370.0 shares to end up with 1,347,611 shares worth $18.73 million. iShares Russell 2000 ETF cut their holdings by -0.29% in the company over the course of the most recent quarter. It now holds a 2.25% position in Health Catalyst Inc. thanks to 1.23 million shares amounting to $17.08 million.
